Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

A recent study published in Neurology explored whether high doses of nicotinamide, a derivative of vitamin B3, could reduce a ...

"During the early stage, it's possible for people with dementia to live well by taking control of their health and wellness, ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

"In people with progressive cognitive decline, the diagnosis of Alzheimer's disease requires a demonstration of amyloid and ...

Once daily oral administration of blarcamesine meaningfully slowed clinical decline in early Alzheimer's disease ... a novel treatment that could be complementary or an alternative to injectable ...

“[Many things] ranging from alternative ... detection and diagnosis of Alzheimer’s. “Anything we can do to detect the disease ...

Declining blood levels of two molecules that occur naturally in the body track closely with worsening Alzheimer's disease, ...